Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

"If you speak with women who have had previous heart attacks, they will often tell you that they had spoken with their doctor ...

Nearly half of adults in Tompkins and nearby counties have hypertension, or high blood pressure, which puts them at risk ...

Mechanically ventilated patients’ respiratory function can be improved with pulmonary rehabilitation, especially IMT and NMES.

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary ...

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the ...